SHAREHOLDER SUPPORT AGREEMENTShareholder Support Agreement • December 6th, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Invesco Asset Management Limited of Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, United Kingdom, a private company limited by shares with company registration number 00 949417 and registered in England and Wales (“Shareholder”), acting as agent for and on behalf of Invesco High Income Fund (“Fund”).
FORM OF SHAREHOLDER SUPPORT AGREEMENTForm of Shareholder Support Agreement • December 6th, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Novartis Pharma AG, a Swiss corporation (“Shareholder”).
FORM OF CONTINGENT VALUE RIGHTS AGREEMENT BETWEEN MEREO BIOPHARMA GROUP PLC and COMPUTERSHARE INC. Dated as of [ ]Contingent Value Rights Agreement • December 6th, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [•] (this “Agreement”), is entered into by and among Mereo BioPharma Group plc, a public limited company incorporated under the laws of England and Wales (“Milan”), and Computershare Inc., a Delaware corporation, as initial Rights Agent (as defined herein).
